ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Its Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer. It is also conducting a Phase II/III clinical trial of varlitinib for gastric cancer; and testing in a single-arm pivotal clinical trial in biliary tract cancer in China. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL Limited. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone65-6222-4235
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.55 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/5/2019 (Estimated)
OptionableNot Optionable
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Frequently Asked Questions
What is ASLAN PHARMACEU/ADR's stock symbol?
ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN."
How were ASLAN PHARMACEU/ADR's earnings last quarter?
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) released its quarterly earnings results on Monday, April, 29th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The business had revenue of $3 million for the quarter, compared to the consensus estimate of $2.70 million. View ASLAN PHARMACEU/ADR's Earnings History.
When is ASLAN PHARMACEU/ADR's next earnings date?
What price target have analysts set for ASLN?
4 brokers have issued 1 year price objectives for ASLAN PHARMACEU/ADR's stock. Their predictions range from $7.00 to $16.00. On average, they anticipate ASLAN PHARMACEU/ADR's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 228.1% from the stock's current price. View Analyst Price Targets for ASLAN PHARMACEU/ADR.
What is the consensus analysts' recommendation for ASLAN PHARMACEU/ADR?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASLAN PHARMACEU/ADR.
What are Wall Street analysts saying about ASLAN PHARMACEU/ADR stock?
Here are some recent quotes from research analysts about ASLAN PHARMACEU/ADR stock:
- 1. According to Zacks Investment Research, "ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. " (5/6/2019)
- 2. HC Wainwright analysts commented, "We note that approved irreversible pan-HER inhibitors have not shown meaningful clinical efficacy in TNBC. These newly published preclinical data have demonstrated that varlitinib is able to inhibit migration, invasion and mammosphere formation in TNBC cells, and therefore, has the potential to deliver clinically meaningful efficacy. Reversible inhibitors could also have a better safety profile than irreversible drugs. We believe ASLAN could seek a partner for further development of varlitinib in TNBC. In the wake of this update, we reiterate our Buy rating and $8.50 price target. Varlitinib showed positive efficacy in first-line BTC. Last week, ASLAN Pharmaceuticals reported positive preliminary data from the ongoing Phase 1b/2 trial of varlitinib + gemcitabine and cisplatin (gem/cis) in first-line biliary tract cancer (BTC)." (1/24/2019)
Has ASLAN PHARMACEU/ADR been receiving favorable news coverage?
Media stories about ASLN stock have trended very positive on Monday, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ASLAN PHARMACEU/ADR earned a coverage optimism score of 3.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of ASLAN PHARMACEU/ADR's key competitors?
Some companies that are related to ASLAN PHARMACEU/ADR include Albireo Pharma (ALBO), Savara (SVRA), Arcus Biosciences (RCUS), Assembly Biosciences (ASMB), Collegium Pharmaceutical (COLL), Achillion Pharmaceuticals (ACHN), Progenics Pharmaceuticals (PGNX), BioDelivery Sciences International (BDSI), Innate Pharma (IPHYF), Forty Seven (FTSV), Prothena (PRTA), Dynavax Technologies (DVAX), Catalyst Pharmaceuticals (CPRX), Karyopharm Therapeutics (KPTI) and Sinovac Biotech (SVA).
What other stocks do shareholders of ASLAN PHARMACEU/ADR own?
Who are ASLAN PHARMACEU/ADR's key executives?
ASLAN PHARMACEU/ADR's management team includes the folowing people:
- Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 46)
- Mr. Kiran Asarpota, VP of Fin. (Age 40)
- Charlie Hsu, Investor Relations Director
- Mr. Ben Goodger, Gen. Counsel (Age 56)
- Chi-Chin Wang, IR & Corp. Devel. Director
When did ASLAN PHARMACEU/ADR IPO?
(ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.
Who are ASLAN PHARMACEU/ADR's major shareholders?
ASLAN PHARMACEU/ADR's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (1.38%), Platinum Investment Management Ltd. (1.21%), Hsbc Holdings PLC (0.62%) and Jane Street Group LLC (0.04%).
Which institutional investors are selling ASLAN PHARMACEU/ADR stock?
ASLN stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC and Baillie Gifford & Co..
Which institutional investors are buying ASLAN PHARMACEU/ADR stock?
ASLN stock was acquired by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd. and Jane Street Group LLC.
How do I buy shares of ASLAN PHARMACEU/ADR?
Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ASLAN PHARMACEU/ADR's stock price today?
One share of ASLN stock can currently be purchased for approximately $3.20.
How big of a company is ASLAN PHARMACEU/ADR?
ASLAN PHARMACEU/ADR has a market capitalization of $102.50 million and generates $11.55 million in revenue each year. The company earns $-42,200,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.
What is ASLAN PHARMACEU/ADR's official website?
How can I contact ASLAN PHARMACEU/ADR?
ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]
MarketBeat Community Rating for ASLAN PHARMACEU/ADR (NASDAQ ASLN)
MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEU/ADR and other stocks. Vote "Outperform" if you believe ASLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
